BioGaia signs exclusive agreement in Uruguay

Report this content

BioGaia has signed an agreement with Abbott LatAm for the exclusive rights to sell BioGaia products under the BioGaia brand in Uruguay. Launch is planned to 2020.

BioGaia primarily focus on pediatrics, gut health and oral health and the probiotic products are available in more than 100 countries.

“Abbott has been our partner for many years in a number of Latin American and also some Asian countries. We see great potential in this partnership and look forward to a successful launch in Uruguay,” says Isabelle Ducellier, CEO of BioGaia.

Latest press releases from BioGaia
06/24/2019 Sales of shares in BioGaia AB
05/09/2019 Annual General meeting of BioGaia 
05/08/2019 BioGaia AB – Interim management statement 1 January – 31 March 2019 

For additional information please contact
Isabelle Ducellier, Managing Director, telephone: +46 8 555 293 00

BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in around 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. www.biogaia.com

Tags:

Subscribe

Quotes

Abbott has been our partner for many years in a number of Latin American and also some Asian countries. We see great potential in this partnership and look forward to a successful launch in Uruguay
Isabelle Ducellier, CEO of BioGaia